

## Amerigroup expands specialty pharmacy precertification list

Effective for dates of service on and after January 1, 2021, the specialty Medicare Part B drugs listed in the table below will be included in our precertification review process.

Federal and state law, state contract language, and CMS guidelines (including definitions and specific contract provisions/exclusions) take precedence over these precertification rules and must be considered first when determining coverage. Noncompliance with new requirements may result in denied claims.

<b>HCPCS or CPT® code</b>	<b>Medicare Part B drugs</b>
C9055	Injection, brexanolone 1 mg
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg
J1627	Injection, granisetron, extended-release, 0.1 mg
J2797	Injection, rolapitant, 0.5 mg
J9153	Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine
J9295	Injection, necitumumab, 1 mg
J9352	Injection, trabectedin, 0.1 mg
Q2049	Injection, doxorubicin hydrochloride, liposomal, imported Lipodox, 10 mg
Q2050	Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
Q5107	Injection, bevacizumab-awwb, biosimilar, (Mvasi), 10 mg
C9047	Injection, caplacizumab-yhdp, 1 mg
J9351	Injection, topotecan, 0.1 mg
Q2043	Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion
J7208	Injection, factor viii, (antihemophilic factor, recombinant), pegylated-aucl, (jivi), 1 i.u.